Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En første-i-human undersøgelse af KK2223 hos deltagere med tilbagefaldt eller ildfast T-celle ikke-Hodgkin-lymfom

29. september 2026 opdateret af: Kyowa Kirin, Inc.

En fase 1, multicenter, open-label, ikke-randomiseret, dosis-eskalering og tilbagefyldningsundersøgelse af KK2223 hos deltagere med tilbagefaldt eller ildfast T-celle ikke Hodgkin-lymfom

The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

72

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • California
      • Duarte, California, Forenede Stater, 91010
        • Ikke rekrutterer endnu
        • City of Hope
        • Ledende efterforsker:
          • Christina Poh
        • Kontakt:
          • Christina Poh
          • Telefonnummer: 916-734-7131
          • E-mail: cpoh@coh.org
      • Orange, California, Forenede Stater, 92868
        • Ikke rekrutterer endnu
        • University of California, Irvine Medical Center - Hematology/Oncology
        • Kontakt:
        • Ledende efterforsker:
          • Lauren Pinter Brown
      • Stanford, California, Forenede Stater, 94305
        • Rekruttering
        • Stanford University School of Medicine
        • Ledende efterforsker:
          • Youn Kim
        • Kontakt:
    • Florida
      • Tampa, Florida, Forenede Stater, 33612
        • Ikke rekrutterer endnu
        • Moffit Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Yumeng Zhang
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Ikke rekrutterer endnu
        • Emory University Medical Center
        • Ledende efterforsker:
          • Pamela Allen
        • Kontakt:
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242
        • Ikke rekrutterer endnu
        • University of Iowa Health
        • Ledende efterforsker:
          • Eric Mou
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Ikke rekrutterer endnu
        • Beth Israel Deaconess Medical Center - Research
        • Kontakt:
        • Ledende efterforsker:
          • Salvia Jain
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110
        • Rekruttering
        • Washington University School of Medicine - Oncology Hospital - Public
        • Ledende efterforsker:
          • Neha Mehta Shah
        • Kontakt:
    • New Jersey
      • Hackensack, New Jersey, Forenede Stater, 07601-2105
        • Ikke rekrutterer endnu
        • Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
        • Ledende efterforsker:
          • Tatyana Feldman
        • Kontakt:
    • New York
      • New York, New York, Forenede Stater, 10021-6007
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
        • Ledende efterforsker:
          • Jasmine Zain
        • Kontakt:
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106
        • Ikke rekrutterer endnu
        • University Hospitals Cleveland Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Kevin Cooper
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Ikke rekrutterer endnu
        • Oregon Health & Science University
        • Kontakt:
        • Ledende efterforsker:
          • Craig Okada
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Ikke rekrutterer endnu
        • University of Pennsylvania - Abramson Cancer Center
        • Ledende efterforsker:
          • Stefan Barta
        • Kontakt:
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • The University of Texas - MD Anderson Cancer Center
        • Ledende efterforsker:
          • Ranjit Nair
        • Kontakt:
      • Bergamo, Italien, 24127
        • Ikke rekrutterer endnu
        • Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
        • Ledende efterforsker:
          • Giuseppe Gritti
        • Kontakt:
      • Bologna, Italien, 40138
        • Ikke rekrutterer endnu
        • Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
        • Kontakt:
        • Ledende efterforsker:
          • Luigi Zinzani Pier
      • Torino, Italien, 10126
        • Ikke rekrutterer endnu
        • AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
        • Kontakt:
        • Ledende efterforsker:
          • Federica Cavallo
    • Torino
      • Candiolo, Torino, Italien, 10060
        • Ikke rekrutterer endnu
        • Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
        • Ledende efterforsker:
          • Umberto Vitolo
        • Kontakt:
      • Madrid, Spanien, 28027
        • Ikke rekrutterer endnu
        • Clinica Universidad de Navarra - Hematología y Hemoterapia
        • Kontakt:
        • Ledende efterforsker:
          • Migue Canales Albendea
    • Barcelona
      • Badalona, Barcelona, Spanien, 8036
        • Ikke rekrutterer endnu
        • Hospital Clinic De Barcelona - Hematología
        • Ledende efterforsker:
          • Pablo Mozas
        • Kontakt:
      • L'Hospitalet de Llobregat, Barcelona, Spanien, 8907
        • Ikke rekrutterer endnu
        • Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
        • Ledende efterforsker:
          • Eva Domingo Domenech
        • Kontakt:
    • Navarre
      • Pamplona, Navarre, Spanien, 31008
        • Ikke rekrutterer endnu
        • Clinica Universidad de Navarra - Hematología
        • Kontakt:
        • Ledende efterforsker:
          • Miguel Canales Albendea

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
  • PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
  • Availability of tumor tissue (current or archival) is required.
  • Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
  • ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
  • Body weight 40 kg to ≤ 200 kg
  • Life expectancy ≥3 months.
  • Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
  • Restrictions on gamete donation and freezing during and after treatment.
  • Ability to provide informed consent and comply with study procedures. -

Exclusion Criteria:

  • Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
  • Pregnant or breastfeeding females, or those intending pregnancy.
  • History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
  • Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
  • Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
  • Use of other investigational drugs within 14 days or 5 half-lives before treatment.
  • Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
  • Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
  • Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
  • Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
  • Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
  • Prolonged QT/QTc interval (e.g., QTcF >480 ms).
  • Active second primary malignancies except specified non-exclusionary cases.
  • CNS involvement.
  • Any condition that may impair compliance or study completion as judged by the Investigator.
  • Known hypersensitivity to any excipients in the drug formulation.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Part One (Dose Escalation)

In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design.

Intravenous infusion

Eksperimentel: Part Two (Backfill)

Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment.

Intravenous infusion

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

Vital signs (mmHg in Systolic/Diastolic blood pressure)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

Pulse rate (beats/min)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

Respiratory Rate (breath/min)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

Temperature (°Celcius)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

ECG parameters (PR interval, QRS interval, QT interval, QTc interval)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years

Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD)

Through study completion, an average of 1.5 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean Blood Drug Concentration
Tidsramme: Through study completion, an average of 1.5 years

The mean drug concentration in the blood

Through study completion, an average of 1.5 years
To evaluate the immunogenicity of KK2223.
Tidsramme: Through study completion, an average of 1.5 years

Incidence of Anti drug antibodies (ADA) in blood

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years

% in Overall Response Rate (ORR)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years

% in Compartment Response (if applicable)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years

Time unit (week/month) in Duration of Response (DOR)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years

Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years

Time unit (week/month) in Time To Response (TTR)

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
Tidsramme: Through study completion, an average of 1.5 years

The maximum drug concentration

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
Tidsramme: Through study completion, an average of 1.5 years

A measure of the overall drug exposure over time

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Tidsramme: Through study completion, an average of 1.5 years

The time taken to reach the maximum drug concentration

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
Tidsramme: Through study completion, an average of 1.5 years

The time required for the drug concentration to decrease by 50%

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Clearance (CL)
Tidsramme: Through study completion, an average of 1.5 years

Rate of drug elimination from the body

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
Tidsramme: Through study completion, an average of 1.5 years

Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues

Through study completion, an average of 1.5 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

2. september 2026

Primær færdiggørelse (Anslået)

1. marts 2029

Studieafslutning (Anslået)

1. september 2030

Datoer for studieregistrering

Først indsendt

12. august 2025

Først indsendt, der opfyldte QC-kriterier

17. september 2025

Først opslået (Faktiske)

25. september 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2223-001

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .